HK Stock Market Move | JIANGXI BIO (06915) rose over 17% to create a new high in the market. Recently, its wholly-owned subsidiary obtained the approval letter for the registration number of the anti-tetanus toxin for animal use.

JIANGXI BIO (06915) rose more than 17%, with the stock price reaching a high of HKD 12.11 in intraday trading, setting a new record high. As of the reporting time, it rose by 17.1% to HKD 12.05, with a trading volume of HKD 39.0691 million. On the news front, JIANGXI BIO announced that its wholly-owned subsidiary, Chifeng Bo'en Pharmaceutical Co., Ltd., recently obtained the "Approval Number Approval Document" for its animal tetanus antitoxin product. The animal tetanus antitoxin is mainly used for the prevention and treatment of animal tetanus infections by neutralizing tetanus toxins, providing passive immunity protection to animals at risk of tetanus infection. The board of directors believes that obtaining the approval document will further enrich the group's product portfolio, lay a foundation for the group to expand into the animal health market, and help enhance the group's overall competitiveness and long-term development potential. According to the prospectus, JIANGXI BIO is the largest provider and exporter of human tetanus antitoxin (TAT) in China, and also a comprehensive anti-serum platform provider. According to Frost & Sullivan data, the company is the largest provider of human TAT in China and globally, with market shares of 65.8% and 36.6% by sales volume in 2024. In 2025, the company's total sales volume of human TAT was 29.9 million units, with 13.5 million units sold in China and 16.4 million units exported to overseas markets.